Subtype
Female Reproductive System Squamous Cell Carcinoma
CI-CAN-00002689Explore in graph →
29 active trials1 evidence items
- NCIt
- C215419
Loading cancer entity…
Subtype
CI-CAN-00002689Explore in graph →
Clinical trials
107 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01295502 |
| Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer |
| unknown |
| Phase 1 |
| 45 |
| Gynecologic Oncology GroupNETWORK |
| 1 |
| Mar 12, 2019 |
| clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2022source: clinicaltrials